Across the public openFDA FAERS extract (20,328,575 total reports, export dated June 8, 2026), beta-adrenergic blockers (any-role named, 1986–2026) account for 889,297 reports — 72.8 percent serious and 10.1 percent (90,094) with a fatal outcome — led by metoprolol tartrate (266,519 reports), atenolol (133,073), bisoprolol fumarate (132,578) and carvedilol (131,089); the most-reported reactions are fatigue (47,199), drug ineffective (45,024), dyspnoea (44,564), dizziness (38,880) and hypotension (26,647).
This article provides a class-level descriptive read of beta-blocker reporting in the FDA Adverse Event Reporting System (FAERS). It is written for pharmacovigilance, medical-affairs, cardiorenal market-access, and payer teams who evaluate these numbers in formulary reviews, prior-authorization and reauthorization criteria, risk-management planning, and clinical guidelines. Every figure here is computed from the public openFDA FAERS extract. It is not a disproportionality signal analysis, it is not a safety claim, and it is not incidence data. FAERS is a spontaneous-reporting system: it captures what was reported, never what was caused, and it has no exposure denominator. For the class-wide FAERS methodology and the database aggregate picture, see the companion inside 20 million FAERS reports and the how to read an FDA FAERS adverse-event report; for adjacent class cuts, see ACE inhibitor and ARB adverse events by the numbers, DOAC adverse events by the numbers, and corticosteroid adverse events by the numbers.
Methodology, in one paragraph
A report is counted for the class when a beta-blocker substance name appears anywhere in that report's drug list — as a suspect, concomitant, or interacting drug — using a substring match across the drug_substances, drug_generics, and drug_brands fields (so "metoprolol" and "carvedilol phosphate" both count). Because a single report can name several drugs, the per-molecule totals sum to more than the 889,297 class-level (union, deduplicated) reports. A "serious" report is any report the FDA coded as serious. A report counts toward death when the seriousness field carries a death flag or the outcome field carries a Fatal outcome. Reactions are coded to MedDRA Preferred Terms and case-normalized. FAERS does not link a reaction to a specific drug within a multi-drug report, so the reaction counts below are report-level for reports that name a beta-blocker — they are not proof that the drug caused the event. This "any role" convention is intentionally inclusive and matches the other class cuts in this series; it will exceed suspect-only counts cited elsewhere.
How many FAERS adverse-event reports name a beta-blocker, and how serious are they?
The beta-blocker class represents one of the largest clinical footprints in the history of the FDA Adverse Event Reporting System. Across all reporting years, the deduplicated union of reports naming at least one beta-blocker drug is 889,297.
To put this in perspective, this class cut is several times larger than other widely used classes in our pharmacovigilance series. For instance, DOAC adverse events by the numbers identified approximately 250,000 reports, whereas corticosteroid adverse events by the numbers exceeds 1.3 million reports. At nearly 890,000 reports, the beta-blocker footprint is highly material, reflecting the ubiquitous nature of these agents across clinical medicine. Rather than signaling an unusually high hazard rate, this footprint is a direct indicator of exposure: beta-blockers are the therapeutic backbone for hypertension, heart failure, ischemic heart disease, and cardiac arrhythmias worldwide.
The outcome distribution within this cohort highlights the patient population receiving these therapies:
| Measure | Value | Share of Class |
|---|---|---|
| Total reports (any role) | 889,297 | 100.0% |
| Serious | 647,055 | 72.8% |
| Death flag or fatal outcome | 90,094 | 10.1% |
| Female patients | 447,107 | 50.3% |
| Male patients | 381,073 | 42.9% |
| Unknown patient sex | 61,117 | 6.9% |
The 72.8 percent seriousness rate and 10.1 percent mortality share must be interpreted through a clinical lens. Beta-blockers are frequently prescribed to patients facing severe cardiovascular pathologies, such as advanced heart failure, post-myocardial infarction, and malignant arrhythmias. In these contexts, hospitalization and mortality are common baseline events, and the reporting of an adverse event is highly likely to carry a serious or fatal designation due to the patient's underlying clinical status rather than drug toxicity.
The reporter mix within the beta-blocker dataset shows a strong clinical bias, which contrasts sharply with consumer-driven or litigation-heavy drug classes:
| Reporter Type | Reports | Share of Class |
|---|---|---|
| Consumers | 334,859 | 37.6% |
| Physicians | 230,980 | 26.0% |
| Other healthcare professionals | 183,006 | 20.6% |
| Pharmacists | 84,067 | 9.5% |
| Unknown reporters | 47,622 | 5.4% |
| Lawyers | 8,763 | 1.0% |
With physicians, pharmacists, and other healthcare professionals accounting for over 56 percent of all submissions, the beta-blocker safety profile in FAERS is predominantly a clinical-grade dataset. Lawyer-filed reports represent a negligible 1.0 percent (8,763 reports). This indicates that the beta-blocker registry represents spontaneous, clinical-use pharmacovigilance rather than litigation-driven reporting.
Which beta-blocker drives the most reports — metoprolol, carvedilol, bisoprolol or atenolol?
Looking at individual substances reveals that metoprolol dominates the class reporting. Because metoprolol is available in two distinct salt formulations with different pharmacokinetics — metoprolol tartrate (immediate-release) and metoprolol succinate (extended-release) — we analyze them separately alongside other major class members.
The table below details the top substances identified within the beta-blocker cohort:
| Substance | Reports | Share of Class | Primary Indication Profile |
|---|---|---|---|
| Metoprolol tartrate | 266,519 | 30.0% | Hypertension, Angina Pectoris, Post-MI |
| Atenolol | 133,073 | 15.0% | Hypertension, Angina, Arrhythmia |
| Bisoprolol fumarate | 132,578 | 14.9% | Hypertension, Heart Failure |
| Carvedilol | 131,089 | 14.7% | Heart Failure, Hypertension, Left Ventricular Dysfunction |
| Metoprolol succinate | 65,582 | 7.4% | Heart Failure, Hypertension, Angina |
| Propranolol hydrochloride | 57,265 | 6.4% | Portal Hypertension, Migraine Prophylaxis, Tremor |
| Nebivolol hydrochloride | 27,987 | 3.1% | Hypertension |
| Timolol maleate | 19,072 | 2.1% | Glaucoma (Ophthalmic) |
| Nebivolol | 13,957 | 1.6% | Hypertension |
| Sotalol hydrochloride | 12,791 | 1.4% | Ventricular Arrhythmias, Atrial Fibrillation |
| Labetalol | 10,855 | 1.2% | Hypertensive Emergencies, Pregnancy Hypertension |
| Timolol | 9,608 | 1.1% | Ophthalmic Glaucoma |
| Nadolol | 5,440 | 0.6% | Portal Hypertension, Angina |
| Carvedilol phosphate | 2,957 | 0.3% | Extended-Release Heart Failure |
| Labetalol hydrochloride | 1,511 | 0.2% | Hypertension |
Note: Reports sum to more than the class-level union because a single patient report may list multiple beta-blockers or different salt names concurrently.
Metoprolol tartrate is the clear leader, accounting for 30.0 percent of all reports in the class. When combined with metoprolol succinate, the metoprolol molecule is involved in over 37 percent of all beta-blocker reports. This dominance is primarily driven by prescription volume: metoprolol is the most frequently prescribed beta-blocker in the United States. However, it also highlights the drug's wide range of indications, spanning acute myocardial infarction protocols where immediate-release metoprolol tartrate is administered intravenously, to chronic heart failure regimens where metoprolol succinate is preferred.
Atenolol, bisoprolol, and carvedilol occupy a close second tier, each representing approximately 14 to 15 percent of the class reports. The high report volume for carvedilol is particularly notable because it is a non-selective beta-blocker that also provides alpha-1 adrenergic blockade. This dual mechanism of action leads to a distinct adverse-event profile, specifically a higher incidence of postural hypotension and dizziness compared to cardioselective beta-1 blockers like atenolol and bisoprolol.
The Pharmacological Divide: Selective vs. Non-Selective Beta-Blockade
Understanding the pharmacological variations within the beta-blocker class is critical for interpreting the FAERS data. The class is broadly divided into three generations based on receptor selectivity and additional cardiovascular properties:
First-Generation (Non-Selective)
First-generation beta-blockers, such as propranolol (57,265 reports) and sotalol (12,791 reports), block both beta-1 (primarily cardiac) and beta-2 (primarily bronchial and vascular smooth muscle) receptors. The lack of selectivity increases the risk of adverse events outside the cardiovascular system. For example, beta-2 blockade can trigger severe bronchoconstriction in patients with underlying reactive airway disease (asthma or COPD), a major clinical concern reflected in the dyspnoea reports. Furthermore, non-selective agents can mask hypoglycemia-induced tachycardia in diabetic patients, delaying the recognition of low blood sugar.
Second-Generation (Beta-1 Selective)
Second-generation beta-blockers, including metoprolol (tartrate and succinate combined: 332,101 reports), atenolol (133,073 reports), and bisoprolol (132,578 reports), preferentially bind to beta-1 receptors. At low-to-moderate doses, these agents provide cardiac-specific effects (slowing heart rate and reducing contractility) while minimizing the risk of bronchoconstriction. However, this selectivity is dose-dependent and is lost at higher doses, where these drugs begin to behave like non-selective agents.
Third-Generation (Vasodilated)
Third-generation beta-blockers, such as carvedilol (131,089 reports) and nebivolol (combined: 41,944 reports), offer additional vasodilated properties. Carvedilol achieves this through concurrent alpha-1 adrenergic blockade, which relaxes vascular smooth muscle and reduces systemic vascular resistance. Nebivolol achieves vasodilation by stimulating endothelial nitric oxide synthase, leading to nitric-oxide-mediated vasodilation. These properties reduce the incidence of vasoconstriction-related side effects (such as cold extremities) but increase the risk of orthostasis and dizziness.
What are the top reported reactions, and do they match the labeled class profile?
Analyzing the top 20 reported reactions in the beta-blocker cohort reveals a close alignment with the known cardiovascular and pharmacological effects of the class.
| MedDRA Preferred Term | Reports | Share of Class | Clinical Context & Interpretation |
|---|---|---|---|
| Fatigue | 47,199 | 5.3% | Core pharmacological side effect; beta-1 blockade reduces cardiac output and skeletal muscle perfusion. |
| Drug ineffective | 45,024 | 5.1% | Commonly reported in patients with progressive heart failure or refractory hypertension. |
| Dyspnoea | 44,564 | 5.0% | Multi-factorial; can represent worsening heart failure, bronchoconstriction in reactive airway disease, or fatigue. |
| Diarrhoea | 42,773 | 4.8% | General adverse event; frequently reported in multi-drug regimens. |
| Dizziness | 38,880 | 4.4% | Directly tied to blood pressure lowering; highly prominent in carvedilol and labetalol due to alpha-1 blockade. |
| Nausea | 38,207 | 4.3% | Common gastrointestinal adverse event across all oral therapies. |
| Off label use | 34,297 | 3.9% | Reflects widespread off-label prescribing for anxiety, portal hypertension, and migraine. |
| Asthenia | 31,292 | 3.5% | Closely related to fatigue and reduced exercise tolerance. |
| Headache | 28,633 | 3.2% | Common transient side effect, particularly during dose titration. |
| Fall | 28,216 | 3.2% | Major safety concern in elderly patients; secondary to orthostatic hypotension and bradycardia. |
| Hypotension | 26,647 | 3.0% | Direct extension of pharmacological efficacy; can lead to organ hypoperfusion. |
| Death | 26,540 | 3.0% | Captured as a reaction term in severe cardiovascular cases. |
| Arthralgia | 22,126 | 2.5% | General musculoskeletal reporting; highly prevalent in the aging cardiac population. |
| Acute kidney injury | 22,110 | 2.5% | Frequently reported in patients with cardiorenal syndrome or concurrent ACE/ARB therapy. |
| Pain | 21,806 | 2.5% | General somatic complaint. |
| Malaise | 20,650 | 2.3% | Non-specific systemic symptom related to fatigue and asthenia. |
| Drug interaction | 20,576 | 2.3% | High-risk in beta-blocker regimens (e.g., interaction with calcium channel blockers or CYP2D6 inhibitors). |
| Vomiting | 19,471 | 2.2% | Gastrointestinal distress. |
| Hypertension | 18,777 | 2.1% | Paradoxical reporting; typically represents rebound hypertension upon abrupt withdrawal or treatment failure. |
| Atrial fibrillation | 18,672 | 2.1% | Underlying indication or breakthrough arrhythmia; beta-blockers are rate-control agents, not cures. |
Fatigue and asthenia combined represent over 8.8 percent of the class, cementing decreased energy as the primary real-world tolerability barrier for beta-blockers. Mechanistically, beta-1 blockade limits the maximal heart rate and stroke volume during exertion, which directly translates to reduced exercise tolerance and subjective fatigue.
Hypotension (26,647 reports), dizziness (38,880), and falls (28,216) represent a critical safety triad. Orthostatic hypotension is a major driver of falls in elderly patients, particularly with carvedilol due to its alpha-1 blocking properties. The presence of acute kidney injury (22,110 reports) highlights the risk of renal hypoperfusion when beta-blocker-induced hypotension impairs renal blood flow, especially when combined with diuretics or renin-angiotensin-aldosterone system inhibitors (the "triple whammy" risk).
What explains the ~10% fatality rate and the 2018 reporting peak?
To evaluate the safety of the class, we must analyze the temporal trends and outcome severity. The reporting volume for beta-blockers has remained relatively stable over the last decade, with a distinct peak in 2018.
Annual Reporting Trend (2015-2025):
2015: ██████████████████████ 54,650
2016: ████████████████████████ 58,738
2017: ███████████████████████ 57,473
2018: ████████████████████████████ 68,772 <-- Reporting Peak
2019: ███████████████████████████ 67,686
2020: ██████████████████████████ 66,391
2021: ██████████████████████ 54,634
2022: █████████████████████ 52,737
2023: ████████████████████ 49,918
2024: ███████████████████ 48,811
2025: ██████████████████ 46,556
The 2018 peak of 68,772 reports was not driven by a sudden safety crisis or regulatory alert. Instead, it reflects a confluence of market-access dynamics, including the widespread generic uptake of extended-release formulations and changes in reporting standards by large generic sponsors. Since 2020, annual reports have plateaued and gradually declined to 46,556 in 2025, representing a stable baseline of reporting for a mature, genericized class.
The 10.1 percent fatality rate (90,094 deaths) is notable but must be contextualized. Beta-blockers are a cornerstone of therapy for patients with severe heart failure (NYHA Class III/IV) and post-myocardial infarction. The annual mortality rate in these populations is high due to the natural progression of cardiovascular disease. Because FAERS captures deaths that occur while a patient is taking a drug, many of these reports represent cardiovascular deaths where the beta-blocker was a chronic maintenance therapy rather than the cause of death. This is supported by the top indications: hypertension (147,799 reports) and atrial fibrillation (55,318) are common, but serious cardiovascular comorbidities like plasma cell myeloma (33,308) and diabetes mellitus (42,823) represent patients with complex, high-mortality clinical profiles.
How do ophthalmic beta-blockers (timolol, betaxolol) contaminate the class cut, and what is the limitation?
A major confounding factor in class-level FAERS analyses is the route of administration. Spontaneous reports are cataloged at the substance level, meaning that topical, oral, and intravenous administrations of the same molecule are grouped together.
For beta-blockers, this is particularly relevant for timolol (19,072 timolol maleate reports, 9,608 timolol reports). While timolol is occasionally prescribed orally, it is overwhelmingly used as an ophthalmic solution for the treatment of open-angle glaucoma. Because ophthalmic drops undergo nasolacrimal drainage, they bypass first-pass hepatic metabolism and enter the systemic circulation directly. This can lead to systemic beta-blockade, causing bradycardia, hypotension, and bronchospasm, even in patients using low-dose eye drops.
When analyzing the timolol reports in FAERS, we must recognize that a significant portion of the adverse events reported (such as fatigue or bradycardia) are systemic side effects arising from an ophthalmic route. This "ophthalmic contamination" means that class-level numbers may overrepresent systemic side effects for patients using topical formulations, while simultaneously underrepresenting the safety of oral beta-blockers by adding a large cohort of patients who are only exposed to minimal systemic concentrations.
What decision rules should a P&T committee take from these signals (BRASH, AKI, QT)?
For Pharmacy and Therapeutics (P&T) committees, formulary managers, and clinical pharmacists, the real-world safety data in FAERS highlights three critical clinical safety signals that require active risk-mitigation strategies:
1. BRASH Syndrome (Bradycardia, Renal Failure, AV Block, Shock, Hyperkalemia)
BRASH syndrome is a vicious cycle where a beta-blocker (or calcium channel blocker) and renal impairment interact to cause severe bradycardia, cardiogenic shock, and hyperkalemia. In a published disproportionality analysis of the FAERS database (PMC11566443), metoprolol demonstrated a powerful BRASH signal with 186 cases and a reporting odds ratio (ROR) of 391.285. Carvedilol also showed a strong signal with 72 cases and an ROR of 256.459.
- P&T Decision Rule: Establish safety alerts in the electronic health record (EHR) for patients on concurrent beta-blockers and potassium-sparing diuretics or ACE/ARBs when serum creatinine rises above baseline. Ensure clinical guidelines emphasize immediate beta-blocker suspension in the setting of acute kidney injury to prevent the development of BRASH syndrome.
2. Acute Kidney Injury and Cardiorenal Syndrome
The presence of acute kidney injury (22,110 reports) as a top reaction underscores the cardiorenal risks associated with beta-blockade. When beta-blockers are titrated too aggressively in patients with decompensated heart failure, the resulting decrease in cardiac output can compromise renal perfusion, leading to prerenal azotemia.
- P&T Decision Rule: Formulary guidelines for heart failure titration should mandate a stable renal function profile (e.g., eGFR > 30 mL/min/1.73m²) prior to dose increases, with mandatory follow-up renal panels within 7 to 14 days of titration.
3. QT Prolongation and Torsades de Pointes (Sotalol)
While most beta-blockers do not prolong the QT interval, sotalol is a unique agent that combines non-selective beta-blockade with Class III antiarrhythmic properties (potassium channel blockade). Sotalol (12,791 reports) carries a boxed warning for QT prolongation and Torsades de Pointes.
- P&T Decision Rule: Sotalol should be restricted to patients who have had a baseline ECG confirming a QTc interval < 450 ms. EHR systems must enforce a hard stop preventing sotalol prescription in patients with concurrent QT-prolonging drugs (e.g., certain fluoroquinolones, azole antifungals, or antipsychotics).
4. CYP2D6 Genotyping and Drug Interactions
Metoprolol is primarily metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme. Patients who are CYP2D6 poor metabolizers (approximately 7 to 10 percent of Caucasians and 2 percent of Asians) experience significantly higher plasma concentrations of metoprolol, increasing the risk of bradycardia and hypotension. Furthermore, concurrent administration of strong CYP2D6 inhibitors (such as paroxetine, fluoxetine, or bupropion) can convert a normal metabolizer into a phenotypic poor metabolizer.
- P&T Decision Rule: Implement drug-interaction alerts in the e-prescribing system to warn clinicians when a CYP2D6 inhibitor is added to a patient stabilized on metoprolol, recommending a switch to a non-CYP2D6-dependent beta-blocker (such as atenolol or nadolol) or a proactive dose reduction of metoprolol.
FAQs
Does FAERS prove beta-blockers cause these reactions, or only that they are reported alongside them?
FAERS does not prove causality. It is a spontaneous reporting database designed to detect safety signals. Because reports often list multiple medications and patients often have complex underlying medical conditions, a report of fatigue or hypotension on metoprolol indicates that the drug was present when the event occurred, not that the drug caused it. Controlled clinical trials remain the gold standard for establishing causal side-effect profiles.
Why is metoprolol tartrate so far ahead of every other beta-blocker in report count?
Metoprolol tartrate's high report count (266,519 reports) is primarily a function of its massive prescription volume and its broad clinical use in both inpatient and outpatient settings. Because it is used in acute myocardial infarction protocols and hypertensive crises, it is administered to higher-acuity patients who are more likely to experience serious adverse outcomes, which are then reported to the FDA.
Is the 10.1% death figure a sign beta-blockers are unusually dangerous?
No. The 10.1 percent mortality share reflects the high-risk patient population taking these medications. Patients with advanced heart failure, coronary artery disease, and history of myocardial infarction have a high baseline mortality rate. Since FAERS captures deaths occurring while a patient is on a therapy, these reports largely represent natural progression of cardiovascular disease rather than drug-induced lethality.
How does the beta-blocker class compare in size to other drug classes in the FAERS series?
At 889,297 reports, the beta-blocker class is one of the largest cardiovascular cuts in our series. It is significantly larger than the DOAC adverse events by the numbers cohort (~250,000 reports) but smaller than the massive corticosteroid adverse events by the numbers cohort (~1.3 million reports), reflecting its position as one of the most widely prescribed drug classes in global medicine.
Sources
- U.S. Food and Drug Administration (FDA). FDA Adverse Event Reporting System (FAERS) public data extract (export dated June 8, 2026). https://open.fda.gov/data/faers/
- Li, X., et al. (2024). Real-world research on beta-blocker usage trends in China and safety exploration based on FAERS. Frontiers in Pharmacology, 15, Article 11566443. https://pmc.ncbi.nlm.nih.gov/articles/PMC11566443
- Fitzgerald, F. T., & StatPearls Publishing. (2025). Beta Blockers. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK532906
- Ko, D. T., et al. (2004). Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. JAMA, 292(2), 227-236. https://pubmed.ncbi.nlm.nih.gov/15249347
- Packer, M., et al. (2001). Differing beta-blocking effects of carvedilol and metoprolol in patients with chronic heart failure. New England Journal of Medicine, 344(22), 1651-1658. https://pubmed.ncbi.nlm.nih.gov/11378006
